Literature DB >> 1503407

Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.

V Gorgoulis1, D Aninos, P Mikou, P Kanavaros, A Karameris, J Joardanoglou, A Rasidakis, M Veslemes, B Ozanne, D A Spandidos.   

Abstract

Immunohistochemical study of epidermal growth factor (EGF), epidermal growth factor receptor (EGFR) and transforming growth factor-alpha (TGF-alpha) expression was performed on paraffin-embedded tissue specimens of 70 squamous cell lung carcinomas. The carcinomas were placed to one of the following eight groups, according to the results of EGF, TGF-alpha and EGFR expression: group 1: none, group 2: only EGFR, group 3: EGFR and TGF-alpha, group 4: EGFR and EGF, group 5: TGF-alpha and EGF, group 6: all three, group 7: only TGF-alpha and finally group 8: only EGF. Statistical analysis of the results revealed that the ratio of squamous cell lung carcinomas with lymph node metastasis was significantly higher in groups 4, 5 and 6 (P less than 0.01). We also examined whether EGF receptors were truncated with the use of two monoclonal antibodies directed against different portions of the receptor (EGFR1 and F4). No truncated EGF receptors were detected. These results suggest that lung carcinomas expressing the molecules EGF/EGFR, TFG-alpha/EGFR or TGF/alpha/EGF/EGFR display pathologic features of more aggressive disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503407

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

Review 1.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.

Authors:  H Dean Hosgood; Idan Menashe; Min Shen; Meredith Yeager; Jeff Yuenger; Preetha Rajaraman; Xingzhou He; Nilanjan Chatterjee; Neil E Caporaso; Yong Zhu; Stephen J Chanock; Tongzhang Zheng; Qing Lan
Journal:  Carcinogenesis       Date:  2008-08-01       Impact factor: 4.944

Review 3.  Vaccine strategies for glioblastoma: progress and future directions.

Authors:  Christopher Jackson; Jacob Ruzevick; Henry Brem; Michael Lim
Journal:  Immunotherapy       Date:  2013-02       Impact factor: 4.196

Review 4.  Tyrosine kinase inhibitors in preclinical development.

Authors:  M L Levitt; P P Koty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Theaflavin-3, 3'-digallate induces epidermal growth factor receptor downregulation.

Authors:  Hideya Mizuno; Yong-Yeon Cho; Feng Zhu; Wei-Ya Ma; Ann M Bode; Chung S Yang; Chi-Tang Ho; Zigang Dong
Journal:  Mol Carcinog       Date:  2006-03       Impact factor: 4.784

6.  The relationship between mast cell infiltration and the expression of PCNA and EGFr in experimental hepatocellular carcinoma of liver and squamous cell carcinoma of stomach in rats.

Authors:  Y Ruan; Z Wu; S Ivankovic
Journal:  J Tongji Med Univ       Date:  1996

7.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

8.  Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface.

Authors:  Jessica P Dawson; Mitchell B Berger; Chun-Chi Lin; Joseph Schlessinger; Mark A Lemmon; Kathryn M Ferguson
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Epidermal growth factor receptor expression in squamous cell lung carcinomas: an immunohistochemical and gene analysis in formalin-fixed, paraffin-embedded material.

Authors:  V Gorgoulis; A Giatromanolaki; A Karameris; C Tsatsanis; D Aninos; B Ozanne; M Veslemes; J Jordanoglou; R Trigidou; H Papastamatiou
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.

Authors:  H Modjtahedi; S A Eccles; G Box; J Styles; C J Dean
Journal:  Cell Biophys       Date:  1993 Jan-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.